1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)" is currently closed and not accepting applications.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This program supports the commercialization readiness of technologies developed through SBIR/STTR programs.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) | Research Funding National Institutes of Health SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization.
The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support.
This includes: Independent replication or confirmation of key studies IND- or IDE-enabling studies Manufacturing scale-up and related quality activities Regulatory and other specialized technical support SBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.
The Commercialization Readiness Pilot (CRP) NOFO provides later-stage research and development and technical assistance to NIH SBIR or STTR Phase II recipients. The CRP program can support R&D that requires significant outsourcing and/or is needed during an active Phase II awards. This funding opportunity requires a prior (active or ended) NIH Phase II award.
New SBIR Phase I and II grant applications should be submitted to PA-27-100 and STTR Phase I and II grant applications should be submitted to PA-27-102 . Phase II recipients that need significant R&D funding to bridge the gap between the SBIR or STTR Phase II award and commercialization should consider the Phase IIB Strategic Breakthrough. See PA-27-101 .
Applicants are strongly encouraged to contact program staff prior to applying to help choose the best funding opportunity for their project. SBIR/STTR Due Dates: Jan. 5, Apr.
5, Sep. 5 PAR-27-098 Expiration Date April 06, 2029 Only United States small business concerns (SBCs) that have had an active NIH SBIR or STTR Phase II or Phase IIB contract or grant award from NIH within the last 36 months are eligible to submit applications for this opportunity. Only one CRP is allowed per Phase II or Phase IIB project.
SBCs with currently active and newly awarded Phase II or Phase IIB awards from one of the participating ICs are also eligible. Engineering and Physical Sciences Medical - Clinical Science
According to the current listing, eligibility includes: Eligible applicants are United States small business concerns that have previously received SBIR or STTR awards. Confirm the full requirements in the official notice before applying.
The published deadline was September 3, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article